Idiopathic localized involutional lipoatrophy (ILIL) is focal loss of subcutaneous tissue without any clinical or histopathological inflammation. Histopathology of ILIL characteristically shows diminutive fat lobules composed of small adipocyte resembling embryonic fat tissue. Immunohistochemical examination reveals a number of CD-68 positive macrophages in the fat lobules. Most reported cases of ILIL were unilateral in young women; we are reporting a case of 4-year-old child with bilateral involvement showing quick spontaneous resolution.
Introduction
Idiopathic localized involutional lipoatrophy (ILIL) is a rare distinctive idiopathic form of localized lipoatrophy. It is characterized by specific focal loss of adipose tissue without antecedent inflammation. We are reporting a 4-year-old male child with bilateral involvement of buttocks with spontaneous resolution within 4 weeks. We are presenting this case because of the rarity of the disease, young age of onset, and quick spontaneous recovery.
Case Report
A 4 year-old male child was brought to us with asymptomatic bilateral depression over buttocks, which they noticed 2 weeks before presentation. There was no history of any injury, injection at the site, drug intake, viral exanthem, and infection before the development of the condition. There was no history suggestive of any autoimmune connective tissue or endocrinal disease. Physical examination revealed nontender, unindurated, well-demarcated, depigmented, symmetrical, depressed plaque of size approximately 45 mm × 25 mm over the left side and 25 × 25 over the right gluteal region [ Figure 1a ]. Similar lesions were not seen elsewhere on the body or in any family member. The child developed itching after application of some indigenous medication followed by erosions. There was no personal or family history suggestive of diabetes. He was born at term by normal vaginal delivery and had normal milstones. Clinical diagnosis of idiopathic form of localized lipoatrophy with a differential diagnosis of lichen sclerosus et atrophicus, morphea, or lupus profundus was kept. Routine hematological and biochemical investigations were within normal limits. Fasting blood sugar, glycated hemoglobin, thyroid function tests, and antinuclear antibodies were normal. Test for human immunodeficiency virus was nonreactive in the child as well as in parents. Skin biopsy was sent for histopathological examination which showed unremarkable epidermis, sparse perivascular lymphohistiocytic infiltrate with hyalinization of dermis, and diminished fat lobules in subcutaneous tissue without inflammation or increased vascularity [ Figure 2a ]. Immunohistochemical staining showed CD-68-positive macrophages [ Figure 2b ]. Diagnosis of ILIL was made, and emollients were prescribed; the child was followed after 4 weeks. There was drastic regression of atrophic lesions bilaterally with repigmentation with residual postinflammatory marks (scratch marks and biopsy site) present [ Figure 1b ].
Discussion
Lipodystrophy is heterogeneous disorder characterized by atrophy and infrequently hypertrophy of adipose tissue. Lipoatrophy refers specifically to selective loss of subcutaneous fat without exudative reaction
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For reprints contact: reprints@medknow.com or fibrosis. Both terms lipoatrophy and lipodystrophy are often used interchangeably. [1] Lipoatrophy may be acquired or inherited. Depending on the extent of involvement, acquired lipoatrophy may be generalized (Lawrence syndrome), partial (Barraquer-Simons syndrome), or localized. Acquired localized lipoatrophy can be caused due to various types of insult to subcutis, for example, repetitive trauma, pressure, abscess, localized connective tissue disease (lupus profundus, panniculitic lymphoma, morphea), and systemic autoimmune diseases (systemic lupus erythematosus, Sjogren's syndrome, dermatomyositis, nephritis, thyroiditis). [2] It may be iatrogenic due to injectables such as insulin (especially nonhuman form), corticosteroids, antibiotics, methotrexate, iron, heparin, vaccines, and growth factors. [1] There is no precise proven pathogenetic mechanism for localized lipoatrophy; however, literature suggests impairment of adipocyte differentiation, adipocyte apoptosis, and mitochondrial dysfunction, as the heterogeneous pathogenesis, reflecting the different subtypes. [3] Localized lipoatrophies with no particular etiology are labeled as idiopathic type. Clinically various types of idiopathic lipoatrophy (ILA) are annular type, abdominal, and semicircular lipoatrophy. [1] Peters and Winkelmann first reported ILA in 1986. It was Dahl et al. in 1996 who observed the distinct histological pattern of adipocytes and classified the variant as ILIL. [4] About 60% of ILA are involutional where single sharply defined, depressed asymptomatic, annular, noninflammatory, nonindurated skin-colored, or depigmented plaque is seen. [1] Rarely, multiple lesions may be seen as in our case. Histologically, these lesions are marked by involution (simulating embryonic adipose tissue) which is characterized by small adipocytes embedded in hyaline connective tissue with many capillaries and non-or pauci-inflammatory cells in the subcutis. [5] Immunoreactants in ILIL are positive for macrophages CD-68 only and negative for T-cells and B-cells. [6] Rest 40% ILA can be classed as inflammatory where multiple lesions of localized lipoatrophy are seen. Histopathologically, the lipocytes are normal associated with diffuse infiltrate of lymphocytes, histiocytes, and plasma cells in the fat lobules; all show immunoreactants to macrophages, T-cell, and B-cell.
ILIL has more commonly been reported in young females. Only few reports are there in males, the cause of which is not clear. Childhood cases reported are rare. Sites most commonly involved are arms, buttocks, thighs, and abdomen. Most of the cases are sporadic except there are two reports of ILIL in siblings. [7] It has been reported with a duration of 2 weeks to an year before patient presents for medical examination, this can be due to asymptomatic nature of the entity. Macrophages are supposed to be involved in the process of localized involutional lipoatrophy. Electron microscopic analysis revealed macrophages becoming lipophages. [8] They secrete various cytokines such as transforming growth factor β, platelet-derived growth factor, interleukin-1, and tumor necrosis factor α, which lead to involution of subcutis.
Histopathologically, ILA has to be differentiated from morphea which shows much more pronounced inflammatory infiltrate in subcutaneous fat than in dermis. Furthermore, trabeculae subdividing the subcutaneous fat are thickened because of inflammation and deposition of new collagen. [9] In lichen sclerosus atrophicus epidermal atrophy, interface dermatitis and collagenization and marked edema in upper and mid dermis are seen and the subcutis is spared.
ILIL may be self-resolving as seen in our case. Anti-inflammatory agents such as steroids, calcineurin inhibitors, or antimalarials can be used in initial phase when lesion is expanding. [10] In long-standing lesions which persist, fillers can be used to improve cosmetic outcome.
Conclusion
Idiopathic localized involution lipoatrophy is a rare entity. There are multiple dermatological diseases which may mimic ILIL. Diagnosis is usually made after excluding other causes of localized atrophy. Histopathology showing localized diminutive adipose tissue which gives clue to diagnosis, and immunohistochemistry showing only CD-68 positivity confirm the diagnosis. ILIL may resolve spontaneously.
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